Anju Software, a life sciences software platform backed by Providence Equity Partners, has acquired the ClinPlus, a division of DZS Software Solutions.
- With this acquisition Anju provides full clinical trial software support from Phase 1 to Phase 4 with a scalable web platform for CROs and pharma companies
- ClinPlus offers a full suite of products used for the performance of clinical trials including EDC, IWRS, CTMS, eTMF, Data Management, Coding and SAS Reporting
About Anju Software
Anju Software is a life sciences enterprise software platform focused on delivering exceptional business application solutions with outstanding customer support. Anju was founded by a group of operating and investment professionals with deep software domain expertise and a proven track record of building software platforms through strategic acquisitions and organic growth.
About DZS Software Solutions
DZS Software Solutions, Inc. is a privately held company founded in 1996 and providing clinical trials software to the biotech and pharmaceutical industry worldwide. DZS will retain DZS Clinical Services, a division of DZS Software Solutions, which is a full service CRO having supported numerous drug approvals, conducted hundreds of clinical studies for both large and small pharmaceutical and biotech companies for a variety of clinical indications. DZS Clinical services use the ClinPlus product suite which is now part of Anju.
About Providence Equity
Providence is a premier asset management firm with over $40 billion in aggregate capital commitments. Providence pioneered a sector-focused approach to private equity investing with the vision that a dedicated team of industry experts could build exceptional companies of enduring value. Since the firm’s inception in 1989, Providence has invested in over 180 companies and has become a leading equity investment firm focused on the media, communications, education and information industries.